
Roche’s Multiple Sclerosis Pill Wins FDA Priority Review, Setting Up a High-Stakes Pharma Race
Roche's experimental oral multiple sclerosis treatment has received FDA priority review, shortening the regulatory clock and raising the probability-weighted value of a key pipeline asset. The designation could pull forward...























